Coverage
-
January 07, 2019
The U.S. Supreme Court on Monday chose not to hear a prominent False Claims Act case linking Gilead Sciences Inc. to sketchy drug manufacturing, a move that follows the U.S. Department of Justice's bombshell vow to end the whistleblower-led litigation.
13 other articles on this case.
View all »